(Exact name of registrant as specified in its charter.)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
Common Stock, par value $0.0001 per share
AZRX
Nasdaq Capital Market
On January 21, 2020, AzurRx BioPharma, Inc. (the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Staff has determined that the Company is now in full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company's common stock, par value $0.0001 per share ("Common Stock"), has been $1.00 per share or greater for the last 10 consecutive trading days.
Accordingly, the Company has regained full compliance with the outstanding deficiency, and Nasdaq has informed the Company in writing that the matter is now closed.
AzurRx BioPharma, Inc. |
By: | /s/ James Sapirstein |
Name: James Sapirstein | |
Title: Chief Executive Officer |